LivaNova PLC (NASDAQ: LIVN) and Lombard Medical (NASDAQ:EVAR) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, valuation, dividends, institutional ownership, profitability and risk.

Volatility and Risk

LivaNova PLC has a beta of 0.52, indicating that its share price is 48% less volatile than the S&P 500. Comparatively, Lombard Medical has a beta of 1.6, indicating that its share price is 60% more volatile than the S&P 500.

Profitability

This table compares LivaNova PLC and Lombard Medical’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
LivaNova PLC 4.63% 9.33% 6.82%
Lombard Medical -320.50% -195.04% -46.78%

Analyst Recommendations

This is a summary of recent ratings and price targets for LivaNova PLC and Lombard Medical, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
LivaNova PLC 1 2 4 0 2.43
Lombard Medical 0 0 0 0 N/A

LivaNova PLC presently has a consensus price target of $76.00, suggesting a potential downside of 5.31%. Given LivaNova PLC’s higher possible upside, equities research analysts clearly believe LivaNova PLC is more favorable than Lombard Medical.

Earnings & Valuation

This table compares LivaNova PLC and Lombard Medical’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio NetIncome Earnings Per Share Price/Earnings Ratio
LivaNova PLC $1.21 billion 3.19 -$62.78 million $1.17 68.60
Lombard Medical $12.17 million 0.51 -$31.03 million ($1.54) -0.14

Lombard Medical has higher revenue, but lower earnings than LivaNova PLC. Lombard Medical is trading at a lower price-to-earnings ratio than LivaNova PLC, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

81.7% of LivaNova PLC shares are held by institutional investors. Comparatively, 40.2% of Lombard Medical shares are held by institutional investors. 0.3% of LivaNova PLC shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

LivaNova PLC beats Lombard Medical on 10 of the 12 factors compared between the two stocks.

About LivaNova PLC

LivaNova PLC is a medical device company focused on the development and delivery of therapeutic solutions. The Company’s segments include Cardiac Surgery, Cardiac Rhythm Management, Neuromodulation and Other. The Cardiac Surgery segment is engaged in the development, production and sale of cardiovascular surgery products. Cardiac Surgery products include oxygenators, heart-lung machines, autotransfusion, mechanical heart valves and tissue heart valves. The Cardiac Rhythm Management segment is engaged in the development, manufacturing and marketing of products for the diagnosis, treatment, and management of heart rhythm disorders and heart failure. Cardiac Rhythm Management products include high-voltage defibrillators Cardiac Resynchronization Therapy device (CRT-D) and low-voltage pacemakers. The Neuromodulation segment is engaged in the design, development and marketing of neuromodulation therapy for the treatment of drug-resistant epilepsy and treatment resistant depression.

About Lombard Medical

Lombard Medical, Inc. is a medical technology company. The Company specializes in developing, manufacturing, and marketing endovascular stent-grafts that address medical needs in the repair of aortic aneurysms. The Company’s Aorfix is an abdominal aortic aneurysm (AAA) stent-graft for the treatment of AAAs with angulation at the neck of the aneurysm of over 90 degrees. The Company supplies Aorfix pre-loaded into a delivery system, Aorflex, which is designed for accurate placement of Aorfix in the abdominal aorta. Once Aorfix is properly placed within the abdominal aorta, it provides a conduit for blood flow, thereby relieving pressure within the weakened or aneurysmal section of the vessel wall, which reduces the potential for the AAA to rupture. It also offers IntelliFlex, which is a delivery system technology created for Aorfix AAA stent graft, and Altura Endovascular Stent Graft System that offers a simple and predictable solution to the treatment of standard AAA anatomies.

Receive News & Ratings for LivaNova PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.